Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.55 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1453002 | 1.00 | TSHR (0.55) | TSHRABCC4MAPTALDH1A1TRPA1 | |
| SCHEMBL131648 | 1.00 | TSHR (0.55) | TSHRABCC4MAPTALDH1A1TRPA1 | |
| SCHEMBL129429 | 1.00 | TSHR (0.55) | TSHRABCC4MAPTALDH1A1TRPA1 | |
| SCHEMBL130045 | 1.00 | TSHR (0.55) | TSHRABCC4MAPTALDH1A1TRPA1 | |
| SCHEMBL130032 | 1.00 | TSHR (0.55) | TSHRABCC4MAPTALDH1A1TRPA1 | |
| SCHEMBL20503164 | 1.00 | TSHR (0.55) | TSHRABCC4MAPTALDH1A1TRPA1 | |
| SCHEMBL1454994 | 1.00 | TSHR (0.55) | TSHRABCC4MAPTALDH1A1TRPA1 | |
| SCHEMBL1452859 | 1.00 | TSHR (0.55) | TSHRABCC4MAPTALDH1A1TRPA1 | |
| SCHEMBL1005861 | 1.00 | TSHR (0.55) | TSHRABCC4MAPTALDH1A1TRPA1 | |
| SCHEMBL131546 | 1.00 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 306 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4387607-A1 | NANOPARTICLE COMPOSITIONS CONTAINING SUGAR FUNCTIONALIZED NUCLEIC ACID CARRIERS | Tiba Biotech LLC (US) | 2024-06-26 | — | — | EP | claimed |
| CN-117897152-A | Nanoparticle compositions containing sugar-functionalized nucleic acid vectors | 蒂巴生物技术有限公司 | 2024-04-16 | — | — | CN | claimed |
| US-20240093238-A1 | NANOPARTICLE COMPOSITIONS CONTAINING SUGAR FUNCTIONALIZED NUCLEIC ACID CARRIERS | TIBA BIOTECH LLC (US) | 2024-03-21 | — | — | US | claimed |
| US-11859201-B2 | Nanoparticle compositions containing sugar functionalized nucleic acid carriers | TIBA BIOTECH LLC (US) | 2024-01-02 | — | — | US | claimed |
| US-20230100837-A1 | NANOPARTICLE COMPOSITIONS CONTAINING SUGAR FUNCTIONALIZED NUCLEIC ACID CARRIERS | TIBA BIOTECH LLC (US) | 2023-03-30 | — | — | US | claimed |
| WO-2023022926-A1 | NANOPARTICLE COMPOSITIONS CONTAINING SUGAR FUNCTIONALIZED NUCLEIC ACID CARRIERS | TIBA BIOTECH LLC (US) | 2023-02-23 | — | — | WO | claimed |
| EP-4132586-A1 | CARRIERS FOR EFFICIENT NUCLEIC ACID DELIVERY | Tiba Biotech LLC (US) | 2023-02-15 | — | — | EP | claimed |
| CN-115702005-A | Vectors for efficient nucleic acid delivery | 蒂巴生物技术有限公司 | 2023-02-14 | — | — | CN | claimed |
| CN-107001532-B | Copolymer and aqueous coating composition using same | 株式会社ADEKA | 2020-11-20 | — | — | CN | claimed |
| EP-0688555-A2 | Hair-growing agent | TANABE SEIYAKU CO., LTD. (JP) | 1995-12-27 | — | — | EP | claimed |
| US-20240218254-A1 | ADDITIVE FOR SURFACE ACTIVATION, AND EMULSION COMPOSITION USING SAME | MIYOSHI OIL & FAT CO., LTD. (JP) | 2024-07-04 | — | — | US | disclosed |
| EP-4387607-A1 | NANOPARTICLE COMPOSITIONS CONTAINING SUGAR FUNCTIONALIZED NUCLEIC ACID CARRIERS | Tiba Biotech LLC (US) | 2024-06-26 | — | — | EP | disclosed |
| CN-118201905-A | Cationic lipid | 武田药品工业株式会社 | 2024-06-14 | — | — | CN | disclosed |
| CN-118108899-A | Curable resin composition, cured product, and method for producing cured product | 东京应化工业株式会社 | 2024-05-31 | — | — | CN | disclosed |
| CN-118109069-A | Resin composition, cured product, and method for producing cured product | 东京应化工业株式会社 | 2024-05-31 | — | — | CN | disclosed |
| EP-0318758-A2 | Multilayered electrophotographical recording material | BASF Aktiengesellschaft (DE) | 1989-06-07 | — | — | EP | disclosed |
| US-4631143-A | Triphenylene derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1986-12-23 | — | — | US | disclosed |
| US-4439425-A | IMMUNOLOGY | CIBA-GEIGY CORPORATION (US) | 1984-03-27 | — | — | US | disclosed |
| EP-0014815-A2 | Peptide derivatives, process for their preparation and intermediates, and pharmaceutical compositions containing one of these compounds | CIBA-GEIGY AG (CH) | 1980-09-03 | — | — | EP | disclosed |
| US-3957928-A | S-AMMONIUM-O-HYDROCARBYL-N-ACYL PHOSPHORAMIDOTHIOATE SALT PRODUCTION AND REACTION WITH ALKYLATING AGENT | CHEVRON RESEARCH COMPANY (US) | 1976-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230100837-A1 | NANOPARTICLE COMPOSITIONS CONTAINING SUGAR FUNCTIONALIZED NUCLEIC ACID CARRIERS | TLR9, TLR3, TSG101 | TSHR 2118/4885ABCC4 1977/4885MAPT 1205/4885 |
| US-20240093238-A1 | NANOPARTICLE COMPOSITIONS CONTAINING SUGAR FUNCTIONALIZED NUCLEIC ACID CARRIERS | TLR9, TLR3, TSG101 | TSHR 2118/4885ABCC4 1977/4885MAPT 1205/4885 |
| US-20240218254-A1 | ADDITIVE FOR SURFACE ACTIVATION, AND EMULSION COMPOSITION USING SAME | HAO2, NOTUM, FFAR2 | TSHR 2408/4885ABCC4 4769/4885MAPT 4421/4885 |
| US-11859201-B2 | Nanoparticle compositions containing sugar functionalized nucleic acid carriers | TLR9, TLR3, TSG101 | TSHR 2118/4885ABCC4 1977/4885MAPT 1205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.